Drug Approval | March 23, 2024
Zydus receives tentative approval from USFDA for Letermovir Tablets
Letermovir tablets, 240 mg and 480 mg had annual sales of USD 289.5 mn in the United States (IQVIA MAT Jan-24)
Letermovir tablets, 240 mg and 480 mg had annual sales of USD 289.5 mn in the United States (IQVIA MAT Jan-24)
New Bioprocessing Production Center in Daejeon to supply products to customers in Asia-Pacific for development and production of biologics
Pharma Solutions operates 10 research and development and/or production sites globally
The pilot plant is focused on scaling up beverage production and will support applications
The MDC business produces components for medical device manufacturers globally with a focus on precious metal alloys and nitinol
KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia
The approved product has an estimated market size of US$ 44.5 million for the twelve months ending January 2024
Lonza plans to invest approximately CHF 500 million to upgrade the facility
Ukrainian marketing approvals for paclitaxel, oxaliplatin and irinotecan mark a significant milestone in the company’s global expansion strategy
Additional capacity broadens Grace’s fine chemical capabilities for API production
Subscribe To Our Newsletter & Stay Updated
